Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.

Under the terms of the agreement, Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.

Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.

Also Read: Novo Nordisk’s Wegovy Tied To Increased Risk ...